Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking two doses of Mounjaro in a single week — or injecting again too soon after your last pen — is not part of the licensed schedule and carries real risks. Mounjaro (tirzepatide) is prescribed as a once-weekly injection; each dose stays active in your body for roughly seven days, so a second injection before that window closes stacks the medicine in your system rather than replacing it. This page explains what that means clinically, what symptoms to watch for, and what to do if it has already happened. Because Mounjaro is a prescription-only medicine, any change to your injection schedule should always be discussed with your prescribing clinician before you act on it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro's active ingredient, tirzepatide, has an elimination half-life of around five days. In practical terms, this means that when your next dose is due (seven days after the previous one) roughly 70–75% of the preceding pen is still circulating. The schedule accounts for this; it is designed so that circulating levels remain steady rather than climbing. Inject a second pen mid-week and you are not topping up an empty tank. You are layering a full dose on top of levels that have barely declined.
The immediate result is a sharp rise in tirzepatide exposure. The hormone-receptor pathways that slow gastric emptying and reduce appetite become far more strongly activated than your body has adjusted to. If you are still on a lower dose (say, 2.5 mg or 5 mg) the gap between your usual level and a doubled level is proportionally large. The tolerability phase at 5 mg exists precisely because the body needs time to adapt; doubling removes that buffer entirely.
This is also why the titration ladder matters. Each four-weekly step lets your system recalibrate. The licensed schedule described in the Mounjaro SmPC on the eMC is not cautious padding, it is the regimen that the clinical trial programme was built around, and the one your prescriber is required to follow.
Most people who accidentally take two doses will notice gastrointestinal symptoms within hours. Nausea tends to arrive first, often more severe than anything experienced on the standard schedule. Vomiting, loose stools and upper abdominal discomfort are common. Dizziness and fatigue can follow if you are not keeping fluids down.
These are unpleasant but, for most people, not dangerous in themselves, provided they resolve within a day or two and you stay hydrated. The greater concern is dehydration from prolonged vomiting or diarrhoea, which can put pressure on the kidneys. Sip water steadily; if you cannot keep any fluid down after several hours, that warrants a call to 111 or your GP rather than waiting it out at home.
There is a rarer but more serious signal to know. On 29 January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis as an infrequent but potentially serious side effect. The symptom to act on urgently is severe, persistent stomach pain that spreads to your back, with or without vomiting, this needs emergency assessment, not home management. Report any suspected adverse effects to the MHRA's Yellow Card scheme, which accepts reports from patients directly. If you are wondering what happens when two doses of Mounjaro are taken and how that compares to simply forgetting a week's injection, the clinical picture for skipping a week is quite different and generally less acute.
If you have already injected a second dose, do not inject again until you have spoken to your prescriber. That is the single most important practical step. Your prescriber needs to know when the doses were taken, which strength is involved, and what symptoms you are experiencing. They will decide whether your next scheduled injection should be delayed, whether your dose should be reviewed, or whether any monitoring is needed.
Do not try to self-adjust by skipping the following week's injection without guidance. Going cold turkey for a fortnight creates its own disruption, appetite tends to rebound and any momentum built during treatment stalls. Equally, the answer is not to carry on as if nothing happened. Your prescriber is the person best placed to map the path back to your normal schedule. If you missed a dose in a previous week and injected twice to compensate, our page on what to do after a missed Mounjaro dose covers the correct approach in detail.
It is also worth being clear about what a double dose cannot do: it will not accelerate your results. The weight-loss trajectory from tirzepatide in clinical trials (around 20% average reduction at the highest doses over 72 weeks) was achieved on the standard once-weekly schedule, not by stacking doses. More medicine in the short term produces more side effects, not faster progress. If you have been prescribed Mounjaro privately and have questions about the cost of continuing your treatment after a disruption, background on how Eli Lilly's UK pricing changes have affected private prescriptions may be relevant to your planning. For a broader overview of how the treatment fits into a managed weight-loss programme, the weight-loss treatment overview sets out the options clearly. Our clinical team profile at Mostafa Damghani explains the prescribing oversight behind every nume, sorry, every nume consultation.
If you are unsure whether your situation needs urgent attention or a routine prescriber message, our frequently asked questions cover a range of dosing queries, or you can reach the team directly via our contact page. Speak to our prescribers if you have any doubt, they are available seven days a week for aftercare support.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.